Business
HeartBeam Reports First Quarter 2025 Results
SANTA CLARA, Calif., May 13, 2025--HeartBeam Reports First Quarter 2025 Results
About this update from Heartbeam, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/69f1957a5b415fa60e003ce4a85411da"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.8rOirXB8joBaiONF3rYSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/69f1957a5b415fa60e003ce4a85411da","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.6H5Sdkiqu31TGvFlbhVzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/69f1957a5b415fa60e003ce4a85411da","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Successfully Met Clinical Endpoints in the VALID-ECG Pivotal Study Showing 93.4% Overall Diagnostic Agreement for Assessment of Arrhythmia","length":138,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Productive Discussions with FDA on 510(k) Submission for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software","length":122,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Signed Strategic Collaboration with AccurKardia to Enhance Commercial Offering for Arrhythmia Assessment","length":104,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Added Two New US Patents to Robust IP Portfolio and Differentiated Position in Remote Cardiac Diagnostics","length":105,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Management to Host Webcast and Conference Call Today at 4:30 p.m. ET","length":68,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":537,"olType":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"SANTA CLARA, Calif., May 13, 2025--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the first quarter ended March 31, 2025.","length":289,"tagName":"p"},{"type":"text","content":"First Quarter & Subsequent 2025 Operational Highlights","length":58,"tagName":"p"},{"type":"text","content":"The Company continues to make significant progress towards commercial readiness with key...